Phase Holographic Imaging (PHI), BioSpherix, SAS, and QIAGEN, formed a technology development alliance to create AI-based process control tools for automated biomanufacturing. The goal is to allow cell-based therapies to be manufactured cost-effectively with superior efficacy and safety.

The complex manufacturing of cell-based therapies remains problematic despite their clinical success. The alliance aims to automate the manufacturing process of cell-based therapies using recent technology developments in cell culturing, analytical instrumentation, and artificial intelligence.

BioSpherix, which has been building cytocentric cell culture equipment since 1983, will provide a sealed and sterile environment to the alliance where cells are cultured at controlled temperature, oxygen, and CO2 levels without human contact. SAS offers AI expertise and software infrastructure to analyze data collected by the QIAGEN and PHI instrumentation. QIAGEN will provide DNA, RNA, and protein molecular data. PHI enters the alliance with non-invasive single-cell imaging data quantifying cellular behavior and morphology.

Wake Forest’s Ecosystem of Regenerative Medicine

The new alliance stems from these companies associated with the RegeneratOR, a component of the regenerative medicine ecosystem in Winston-Salem, NC, called the Regenerative Medicine Hub (RegenMed Hub™). The RegeneratOR is a program of the RegenMed Development Organization in association with its collaborative research partner, the Wake Forest Institute for Regenerative Medicine. The RegenMed Hub, based in the Innovation Quarter, draws together the resources and talent available through the Wake Forest enterprise and the surrounding region.

Previous articleSupreme Court Grapples with the Enablement Standard for Functional Genus Patent Claims
Next articleFrom Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines